Abstract #0621

Product-Ratios of Metabolite Concentrations as Potential Alzheimer’s Disease Biomarker

Ariane Fillmer¹, Laura Göschel^2,3, Semiha Aydin¹, Theresa Köbe^2,3,4,5, Agnes Flöel^2,3,6, and Bernd Ittermann¹

¹Physikalisch-Technische Bundesanstalt (PTB), Braunschweig and Berlin, Germany, ²Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Klinik und Hochschulambulanz für Neurologie, Charité - Universitätsmedizin Berlin, Berlin, Germany, ³Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre, Douglas Mental Health University Institute, Montreal, QC, Canada, ⁵Department of Psychiatry, McGill University, Montreal, QC, Canada, ⁶Department of Neurology, University Medicine Greifswald, Greifswald, Germany

Previous studies have reported changes in the concentrations of several neurometabolites in Alzheimer’s disease (AD). Nevertheless, group differences of these metabolites between healthy controls, mild cognitively impaired, and AD patients remain small. The transition to ultrahigh fields enables the assessment of further metabolites, and some of them, like GABA and glutamate, have been observed to change in AD. In this study, the combination of several metabolite concentrations associated with AD into a product-ratio to serve as a stronger MRS biomarker for Alzheimer’s than individual concentrations of metabolites, and their relationship with volume of brain structures and memory performance is investigated.

This abstract and the presentation materials are available to members only; a login is required.

Join Here